GSK Tries To Chase Down Pfizer With Phase III Pentavalent Meningococcal Vaccine Data
Phase III data for a vaccine combining Bexsero and Menveo demonstrated non-inferiority. GSK hopes to file it for approval soon, while Pfizer’s candidate has an October FDA action date.
You may also be interested in...
The company presented data for its MenABCWY vaccine, but it still hasn’t specified the timing for approval. While its launch would lag Pfizer’s, GSK has an advantage in terms of data as well as leadership in the space.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.